系统综述:粪便免疫化学试验升高与粪便潜血阳性结果相关的死亡率
该系统综述检索了Medline和Embase(截至2024年2月9日),纳入10项研究(3项gFOBT、7项FIT),共报告14,687,625份粪便血红蛋白结果。粪便血红蛋白升高与全因、非结直肠癌及特定原因死亡率(包括心血管、消化和呼吸系统疾病)风险增加相关;因适合每类粪便血红蛋白检测的结果有限,未进行Meta分析。作者认为需开展基于人群的研究以明确该关联是否见于有症状患者。
要点
- 粪便血红蛋白升高与全因、非结直肠癌及特定原因死亡率升高相关。
- 全因死亡粗风险比在5项研究中升高,RR范围1.11至2.95。
- 非结直肠癌死亡RR范围1.09至2.79;未进行Meta分析。
核心结论
- 粪便血红蛋白升高者的全因、非结直肠癌及特定原因死亡率似乎更高。
- 作者认为需开展基于人群的研究以明确该关联是否见于有症状患者。
研究设计与样本
- 系统综述,检索Medline和Embase(2024年2月9日),纳入报告粪便免疫化学试验或愈创木脂粪便潜血试验后死亡率的研究。
- 共纳入10项研究:3项报告gFOBT结果,7项报告FIT结果,均作为筛查试验;合计报告14,687,625份粪便血红蛋白结果。
主要发现
- 粪便血红蛋白升高与全因、非结直肠癌及特定原因死亡率(包括心血管、消化和呼吸系统疾病死亡)风险增加相关。
- 全因死亡粗风险比来自6项研究(3项gFOBT、3项FIT),其中5项显示风险增加,RR范围为1.11(95% CI: 1.06-1.16)至2.95(95% CI: 2.85-3.05)。
- 非结直肠癌死亡RR范围为1.09(95% CI: 1.04-1.15)至2.79(95% CI: 2.70-2.89)。
- 因适合每类粪便血红蛋白检测的结果有限,未进行Meta分析。
局限性
- 因适合每类粪便血红蛋白检测的结果有限,未进行Meta分析。
- 作者认为需开展基于人群的研究以明确该关联是否见于有症状患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Faecal haemoglobin (f-Hb) testing is used in colorectal cancer (CRC) screening and increasingly to guide the investigation in patients with symptoms suggestive of CRC. Studies have demonstrated increased mortality with raised f-Hb. AIMS: To assess the association of raised f-Hb with all-cause, non-CRC (any cause excluding CRC) and cause-specific mortality. METHODS: We searched Medline and Embase on 9 February 2024 to identify papers reporting mortality after faecal immunochemical (FIT) or guaiac faecal occult blood tests (gFOBT). The primary outcome was all-cause mortality following a positive compared to a negative test. RESULTS: The search identified 3155 papers. Ten met the inclusion criteria: three reported gFOBT and seven reported FIT results, as screening tests. These reported a total of 14,687,625 f-Hb results. Elevated f-Hb was associated with an increased risk of all-cause, non-CRC and cause-specific mortality including death from cardiovascular, digestive and respiratory diseases. Crude risk ratios for all-cause mortality with a positive versus negative test were derived from six papers (three reporting gFOBT, three FIT). An increased risk was demonstrated in five, with RRs ranging from 1.11 (95% CI: 1.06-1.16) to 2.95 (95% CI: 2.85-3.05). For non-CRC mortality risk, RRs ranged from 1.09 (95% CI: 1.04-1.15) to 2.79 (95% CI: 2.70-2.89). We did not perform meta-analysis due to a limited number of papers reporting suitable results for each type of f-Hb test. CONCLUSIONS: All-cause, non-CRC and cause-specific mortality appear higher in those with raised f-Hb. Population-based studies are warranted to elicit whether this association occurs in symptomatic patients.
引用
- Malcolm FL, Yapa AKDS, Wong ZY, et al. Systematic review: Mortality associated with raised faecal immunochemical test and positive faecal occult blood results. Aliment Pharmacol Ther. 2024. PMID: 39162338. doi:10.1111/apt.18208
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。